The management of orphan drugs in Italy - Focus on haemophilia in the region of Umbria
DOI:
https://doi.org/10.54844/hamp.2022.0032Abstract
none
References
National Observatory on the Use of Medicines. [The use of Medicines in Italy. National Annual Report 2020.] Rome: Italian Medicines Agency, 2021.
Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, Kitchen S, Llinas A, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19:e1-e47.
Abbonizio F, Arcieri R, Giampaolo A. [Italian Association of Hemophilia Centers (AICE). National Registry of Congenital Coagulation Disorders. 2018 Report (ISTISAN reports 20/14).] Rome: Italian National Institute of Health, 2020.
Abbonizio F, Giampaolo A, Riccioni R, Arcieri R, Hassan HJ. [Italian Association of Hemophilia Centers (AICE). National Registry of Congenital Coagulation Disorders. 2016 Report (ISTISAN reports 18/1).] Rome: Italian National Institute of Health, 2018.
Berntorp E, Andersson NG. Prophylaxis for Hemophilia in the Era of Extended Half-Life Factor VIII/Factor IX Products. Semin Thromb Hemost 2016;42:518-525.
Cancanelli L, Mirarchi SA, Pasut E, Salanitro MP, Stoppa S. [The impact of extended half-life factors on FVIII consumption: the hospital pharmacist’s perspective.] GIHTAD 2018;11:7.
Mannucci PM. Hemophilia therapy: the future has begun. Haematologica 2020;105:545-553.
Published
Issue
Section
Downloads
License
Copyright (c) 2023 Hospital Administration and Medical Practices
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
This work is licensed under a